This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Provigil (Sparlon)

Teva Pharmaceutical Industries Ltd.

Drug Names(s): modafinil, Attenace, Modiodal (Japan), Vigil, Modasomil, CN-801, AFT-801

Description: The precise mechanism by which Provigil exerts its wake-promoting effects is still unclear. At pharmacologically relevant concentrations, it does not bind to or inhibit a number of receptors and enzymes potentially relevant for sleep/wake regulation. While Provigil-induced wakefulness can be attenuated by the alpha1-adrenergic receptor antagonist, prazosin, Provigil is inactive in other in vitro assay systems known to be responsive to alpha-adrenergic agonists. Provigil is not a direct- or indirect-acting dopamine receptor agonist, though it binds to the dopamine transporter and inhibits dopamine reuptake. However, there is conflicting evidence about the relevance of this.

Sparlon was the new formulation and dosage strength of modafinil, the active ingredient in Provigil Tablets, for ADHD, an indication that was suspended due to a potential side effect.

Deal Structure: Cephalon and Takeda
In June 2006, Cephalon and Takeda announced that the companies have entered into an agreement to co-promote Provigil Tablets [C-IV] in the United States. The co-promotion agreement runs for three years with an option to renew annually.

As part of the agreement, Cephalon also has an option to utilize the Takeda sales force for the promotion of Nuvigil (armodafinil) Tablets. Cephalon will pay Takeda a royalty based on certain sales criteria for Provigil and Nuvigil. Under the agreement, Cephalon will retain all responsibility for the development, manufacture, distribution and sale of Provigil. Cephalon and Takeda will form a joint commercial committee to manage the promotion of Provigil.

Alfresa, Mitsubishi Tanabe and Cephalon
In June 1998, Alfresa Pharma acquired the right to develop, manufacture and market Provigil in Japan from Cephalon.

In April 2006, Alfresa Pharma signed an agreement with Tanabe Seiyaku on modafinil. Upon receiving...See full deal structure in Biomedtracker

Partners: Takeda Pharmaceutical Company Ltd Mitsubishi Tanabe Pharma Corporation Alfresa Pharma Corporation


Provigil (Sparlon) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug